Beyond Blood Counts: Hematocrit Dynamics in Breast Cancer Monitoring

Article *in* KIU Journal of Health Sciences · February 2024

DOI: 10.5958 /KJHS-2023-3-2-03

3 authors:

Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,329 PUBLICATIONS **8,468** CITATIONS
SEE PROFILE

Getrude Uzoma Obeagu
Kampala International University (KIU)
321 PUBLICATIONS **2,310** CITATIONS
SEE PROFILE

Patrick M. Aja
Kampala International University (KIU)/Ebonyi State University, Nigeria
152 PUBLICATIONS **1,475** CITATIONS
SEE PROFILE

REVIEW ARTICLE

Beyond Blood Counts: Hematocrit Dynamics in Breast Cancer Monitoring

*Obeagu, E.I.[1], Obeagu, G.U.[2] and Aja, P.M.[3,4]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda.
[2]School of Nursing Science, Kampala International University, Uganda.
[3]Department of Biochemistry, Faculty of Science, Ebonyi State University, P.M.B. 053 Abakaliki, Ebonyi State, Nigeria
[4]Department of Biochemistry, Kampala International University, Western Campus, Uganda

ABSTRACT

This review delves into the expanding role of hematocrit dynamics as a critical parameter in the monitoring and management of breast cancer. Moving beyond conventional reliance on blood counts, the analysis explores the intricate relationship between hematocrit fluctuations and various facets of breast cancer progression, treatment response, and overall patient outcomes. The review aims to elucidate the potential of hematocrit as a dynamic biomarker, offering insights into the underlying physiological changes associated with the disease. By examining the correlation between hematocrit levels and different stages of breast cancer, treatment modalities, and patient-specific factors, this review seeks to enhance the current understanding of hematocrit's prognostic and predictive value. Additionally, it explores the implications of hematocrit dynamics on therapeutic strategies, emphasizing the need for personalized approaches in breast cancer care. The synthesis of available evidence in this review underscores the significance of considering hematocrit as a valuable and dynamic parameter in breast cancer monitoring. The integration of hematocrit dynamics into clinical practice has the potential to refine diagnostic and prognostic frameworks, contributing to a more comprehensive and personalized approach to breast cancer management. In conclusion, this review provides a critical examination of the evolving landscape beyond blood counts, highlighting the emerging importance of hematocrit dynamics in enhancing our understanding and management of breast cancer.

Keywords: Breast cancer, Hematocrit, Disease monitoring, Biomarkers, Oncology, Hematological parameters, Cancer dynamics.

*Corresponding Author
Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161.

Citing this Article
Obeagu, E.I., Obeagu, G.U. and Aja, P.M.. Beyond Blood Counts: Hematocrit Dynamics in Breast Cancer Monitoring. KIU J. Health Sci, 2023: 3(2);

Conflict of Interest: None is declared

INTRODUCTION

Breast cancer remains a significant global health challenge, necessitating continuous refinement of diagnostic and monitoring strategies. Traditional assessments predominantly rely on blood counts; however, recent research has uncovered the potential significance of hematocrit dynamics in the context of breast cancer. Hematocrit, a measure of red blood cell volume, has traditionally been associated with oxygen-carrying capacity, but its role extends beyond conventional hematological considerations (1-3). This review aims to explore the evolving landscape of hematocrit dynamics in breast cancer monitoring, moving beyond the confines of routine blood count parameters. As breast cancer exhibits diverse biological behaviors and responses to treatment, there is a growing recognition of the need for nuanced and personalized diagnostic approaches. Hematocrit, as a dynamic biomarker, holds promise in offering additional insights into the underlying physiological changes associated with breast cancer progression and therapeutic interventions (4-5).

The intersection between breast cancer and hematocrit dynamics is multifaceted. Breast cancer, a disease known for its multifactorial impact on the host, may exert systemic effects, potentially influencing erythropoiesis, inflammation, and angiogenesis, thus impacting hematocrit levels. Recent studies have started unraveling these connections, hinting at the possibility of hematocrit serving as a broader biomarker in the context of breast cancer (6). Understanding hematocrit dynamics in breast cancer extends beyond mere correlation. It promises insights into the disease's systemic influence, therapeutic effects on the hematopoietic system, and potential implications for long-term patient outcomes.

This paper aims to explore the evolving understanding of hematocrit dynamics in breast cancer monitoring, emphasizing its potential clinical implications. It delves into emerging evidence suggesting associations between hematocrit alterations, disease progression, therapeutic responses, and patient prognosis. Additionally, it outlines potential avenues for integrating hematocrit assessments into comprehensive breast cancer monitoring protocols, envisioning a role for hematocrit as a supplementary biomarker for more effective disease management. This paper aims to unravel the evolving significance of hematocrit dynamics beyond its conventional role in blood counts, exploring its potential as a valuable adjunct in the comprehensive monitoring and management of breast cancer. By elucidating these dynamics, we aim to contribute to the growing body of knowledge that may shape more nuanced and comprehensive approaches to breast cancer care.

Hematocrit Dynamics and Breast Cancer

The relationship between hematocrit dynamics and breast cancer represents a complex interplay influenced by various factors impacting erythropoiesis, inflammation, and angiogenesis. While traditionally considered a measure of red blood cell volume, recent investigations have unveiled a potential correlation between alterations in hematocrit levels and breast cancer dynamics. Breast cancer, as a systemic disease, can exert effects on the host's physiology. Tumor-induced alterations in cytokine profiles, such as elevated levels of inflammatory cytokines, might contribute to changes in erythropoiesis and affect hematocrit levels (7). Tumor progression often involves angiogenesis to support tumor growth (8). This process may contribute to alterations in oxygen availability, leading to tissue hypoxia, which could indirectly impact erythropoiesis and hematocrit levels. Chronic inflammation associated with breast cancer may influence hematopoietic activity, affecting the production and turnover of red blood cells, potentially reflecting in alterations in hematocrit levels (9). Cancer therapies, including chemotherapy and targeted treatments, might affect hematocrit dynamics. Chemotherapy-induced myelosuppression or drug-related toxicities could impact erythropoiesis and subsequently alter hematocrit levels (10).

https://kjhs.kiu.ac.ug https://doi.org/10.5958 /KJHS-2023-3-2-03 KJHS 3(2); 2023. Page (25-29)

Recent studies suggest associations between baseline hematocrit levels, fluctuations during treatment, and disease outcomes in breast cancer cohorts (11-12). This indicates the potential of hematocrit as a non-traditional biomarker for gauging disease activity and therapeutic responses. Preliminary evidence hints at potential associations between hematocrit alterations and long-term survival outcomes in breast cancer patients. Understanding these dynamics may have implications for prognostication and risk stratification. Changes in hematocrit levels during or after cancer treatment could serve as indicators of therapeutic responses, aiding clinicians in assessing treatment efficacy and modifying regimens accordingly (13). Integrating assessments of hematocrit dynamics into routine monitoring protocols for breast cancer patients could provide additional insights into disease progression and treatment responses. Further research is warranted to validate the clinical utility of hematocrit as a biomarker in breast cancer management.

Clinical Applications and Future Directions

Clinical Applications

Integrating assessments of hematocrit dynamics alongside traditional markers may enhance disease monitoring in breast cancer patients. Tracking changes in hematocrit levels could offer additional insights into disease progression and treatment responses (14). Hematocrit alterations during or after specific treatments could serve as indicators of therapeutic responses. Monitoring hematocrit dynamics may aid clinicians in evaluating treatment efficacy and making timely adjustments (15). Exploring associations between baseline hematocrit levels, fluctuations during treatment, and long-term survival outcomes may contribute to risk stratification models and prognostication strategies, aiding in identifying high-risk patient cohorts (16-17). Utilizing hematocrit dynamics as part of personalized medicine approaches could assist in tailoring treatment strategies based on individual patient responses and profiles. This could lead to optimized therapeutic interventions (18).

Future Directions

Investigating the molecular mechanisms underlying hematocrit changes in breast cancer can provide deeper insights into the biological processes driving these alterations. Exploring the interactions between hematocrit dynamics and specific molecular pathways may uncover novel therapeutic targets and predictive markers. Conducting long-term, prospective studies is essential to track hematocrit dynamics over the entire course of breast cancer, from diagnosis through treatment and follow-up. This longitudinal approach can elucidate patterns of hematocrit changes and their associations with disease progression and treatment responses. Combining hematocrit data with advanced imaging technologies, such as magnetic resonance imaging (MRI) or positron emission tomography (PET), could offer a more comprehensive understanding of breast cancer biology. Integrating hematocrit dynamics with imaging findings may improve the accuracy of diagnosis and monitoring.

Initiating clinical trials focused on interventions targeting hematocrit dynamics in breast cancer is crucial. Assessing the impact of therapies aimed at modulating hematocrit levels on treatment outcomes can provide valuable information for developing novel treatment strategies. Applying machine learning algorithms to large datasets encompassing hematocrit dynamics, clinical parameters, and genomic information may unveil hidden patterns and aid in developing predictive models for breast cancer prognosis and treatment response. Investigating the potential of hematocrit dynamics for patient stratification can guide more personalized treatment approaches. Identifying subgroups of patients who may benefit from specific interventions based on their hematocrit profiles can optimize therapeutic strategies. Encouraging international collaboration and data sharing initiatives can facilitate the pooling of diverse datasets, enabling researchers to analyze a broader

spectrum of hematocrit dynamics in different populations and subtypes of breast cancer.

Conclusion

This review has shed light on the expanding role of hematocrit dynamics in breast cancer monitoring, surpassing the conventional boundaries of blood count assessments. The investigation into hematocrit fluctuations as a dynamic biomarker has revealed intricate associations with various facets of breast cancer, including disease progression, treatment responses, and overall patient outcomes. The insights provided by this review underscore the importance of looking beyond blood counts and embracing hematocrit dynamics as a valuable dimension in the ongoing pursuit of refined breast cancer monitoring and management.

REFERENCE

1. Trapani D, Ginsburg O, Fadelu T, Lin NU, Hassett M, Ilbawi AM, Anderson BO, Curigliano G. Global challenges and policy solutions in breast cancer control. Cancer treatment reviews. 2022; 104:102339.
2. Mutebi M, Anderson BO, Duggan C, Adebamowo C, Agarwal G, Ali Z, Bird P, Bourque JM, DeBoer R, Gebrim LH, Masetti R. Breast cancer treatment: A phased approach to implementation. Cancer. 2020; 126:2365-78.
3. Obeagu EI, Babar Q, Vincent CC, Udenze CL, Eze R, Okafor CJ, Ifionu BI, Amaeze AA, Amaeze FN. Therapeutic targets in breast cancer signaling: A review. Journal of Pharmaceutical Research International. 2021 Dec 13;33(56A):82-99.
4. Obeagu EI, Ahmed YA, Uzoma G. Biomakers of breast cancer: Overview. Int. J. Curr. Res. Biol. Med. (2023). 8(1): 8-16
5. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO, Uduchi IO. Advances in Therapeutic Strategies of Immunotherapy in Cancer Treatment. World Journal of Pharmacy and Pharmaceutical Sciences. 2021;10(8):2144-64.
6. Natalucci V, Virgili E, Calcagnoli F, Valli G, Agostini D, Zeppa SD, Barbieri E, Emili R. Cancer related anemia: an integrated multitarget approach and lifestyle interventions. Nutrients. 2021;13(2):482.
7. Zhang J, Xia Y, Sun J. Breast and gut microbiome in health and cancer. Genes & Diseases. 2021;8(5):581-9.
8. Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences. 2020; 77:1745-70.
9. Poz D, De Falco E, Pisano C, Madonna R, Ferdinandy P, Balistreri CR. Diagnostic and prognostic relevance of red blood cell distribution width for vascular aging and cardiovascular diseases. Rejuvenation Research. 2019;22(2):146-62.
10. Huang W, Li X, Chen Y, Li X, Chang MC, Oborski MJ, Malyarenko DI, Muzi M, Jajamovich GH, Fedorov A, Tudorica A. Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challenge. Translational oncology. 2014;7(1):153-66.
11. Gilmore N, Mohile S, Lei L, Culakova E, Mohamed M, Magnuson A, Loh KP, Maggiore R, Belcher E, Conlin A, Weiselberg L. The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy. Breast Cancer Research. 2021; 23:1-1.
12. Simoes R, Silva LM, de Oliveira AN, Alves MT, Pestana RM, de Souza ID, Oliveira HH, Soares CE, Sabino AD, Gomes KB. Identification of clinical and laboratory variables associated with cardiotoxicity events due to doxorubicin in breast cancer patients: A 1-Year Follow-Up Study. Cardiovascular Toxicology. 2021; 21:106-14.
13. Epstein JB, Thariat J, Bensadoun RJ, Barasch A, Murphy BA, Kolnick L, Popplewell L, Maghami E. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA: a cancer journal for clinicians. 2012;62(6):400-22.
14. Li K, Ji J, Li S, Yang M, Che Y, Xu Z, Zhang Y, Wang M, Fang Z, Luo L, Wu C. Analysis of the Correlation and Prognostic Significance of Tertiary Lymphoid Structures in Breast Cancer: A Radiomics-Clinical Integration Approach. Journal of Magnetic Resonance Imaging. 2023.
15. Goyette RE, Key NS, Ely EW. Hematologic changes

in sepsis and their therapeutic implications. InSeminars in respiratory and critical care medicine 2004; 25(06):645-659. Copyright© 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

16. Chioncel O, Collins SP, Greene SJ, Pang PS, Ambrosy AP, Antohi EL, Vaduganathan M, Butler J, Gheorghiade M. Predictors of post-discharge mortality among patients hospitalized for acute heart failure. Cardiac Failure Review. 2017;3(2):122.
17. Luo M, Chen Y, Cheng Y, Li N, Qing H. Association between hematocrit and the 30-day mortality of patients with sepsis: a retrospective analysis based on the large-scale clinical database MIMIC-IV. PLoS one. 2022;17(3): e0265758.
18. Virag M, Leiner T, Rottler M, Ocskay K, Molnar Z. Individualized hemodynamic management in sepsis. Journal of personalized medicine. 2021;11(2):157.